Gerald Raymond, MD
Neurology with Special Qualifications in Child Neurology · Baltimore, MDNPI 1386686467
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $11,800 of the $11,922 with a category attached, or 99.0%. 4 manufacturers reported payments, led by Ionis Pharmaceuticals, Inc. at 60.0% of the total. 2025 is the largest year on record at $7,150, 3.2 times the $2,250 reported in 2022.
Across 10 payments — averaging $1192.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ionis Pharmaceuticals, Inc.$7K
- Travere Therapeutics, Inc.$5K
- Sanofi$95
- Chiesi USA, Inc.$27
Across 7 payments — averaging $5630.23 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$31K
- Takeda Pharmaceuticals U.S.A., Inc.$7K
- Sanofi US Services Inc.$2K
What the payments were for
- Consulting fees$11,80099%
- Food & beverage$1221%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ionis Pharmaceuticals, Inc. | 4 | $7,150 |
| Travere Therapeutics, Inc. | 4 | $4,650 |
| Sanofi | 1 | $95 |
| Chiesi USA, Inc. | 1 | $27 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- (810) Chenodal$4,650
How this compares
$11,922 in reported general payments places this provider in the 85th percentile of 36 neurology with special qualifications in child neurology providers in Maryland.
See all neurology with special qualifications in child neurology providers in Maryland →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Sapropterin Dihydrochloride | 20 | $135,940 |
| XifaxanRifaximin | 14 | $44,684 |
Paid to pharmacies, not to this prescriber.
Other neurology with special qualifications in child neurology in Baltimore
- Bilal SitwatBaltimore$42K
- Jessica NanceBaltimore$19K
- Carl StafstromBaltimore$16K
- Constance Smith HicksBaltimore$14K
- Kristin BarananoBaltimore$11K
- Anne ComiBaltimore$7K
- Chethan RaoBaltimore$2K
- Stephen ThompsonBaltimore$2K
- Peggy LazerowBaltimore$1K
- Christopher OakleyBaltimore$705
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.